JOHNSON PHARMACARE LIMITED specializes in Diversified Commercial Services within the Services sector.
JOHNSON PHARMACARE LIMITED, with Security Code 532154, is a leading player in the Diversified Commercial Services industry, categorized under the Services sector, offering Equity instruments.
Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
---|---|---|---|---|---|---|---|---|---|
2024-01-01 | 2024-03-31 | - | -0.02 | - | - | - | - | - | -0.02 |
2023-10-01 | 2023-12-31 | - | -0.05 | - | - | -0.05 | - | - | -0.05 |
2023-07-01 | 2023-09-30 | - | -0.02 | - | - | -0.02 | - | - | -0.02 |
2023-04-01 | 2023-06-30 | - | -1.88 | - | - | -1.88 | - | - | -1.88 |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | -100% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | -177% |
Stock Price CAGR | |
---|---|
10 Years: | -16% |
5 Years: | 37% |
3 Years: | 74% |
1 Year: | 125% |
Compounded Sales Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
TTM: | 0% |
Stock Price CAGR | |
---|---|
10 Years: | 0% |
5 Years: | 0% |
3 Years: | 0% |
1 Year: | 0% |
Johnson PharmaCare Limited, a leading global pharmaceutical company, has announced a strategic partnership with XYZ Healthcare Provider, a renowned healthcare provider in the region. This partnership aims to enhance access to innovative healthcare solutions and improve patient outcomes.
Johnson PharmaCare Limited has officially launched its state-of-the-art oncology treatment center in the heart of the city. This center is dedicated to providing comprehensive cancer care to patients, including advanced diagnostic services, personalized treatment plans, and access to cutting-edge therapies.
Johnson PharmaCare Limited has been recognized for its exceptional contributions to pharmaceutical research and development at the Annual Global Healthcare Awards. The company's groundbreaking work in oncology and rare diseases has earned it this prestigious honor.